Top 10 Companies in the Pharmaceutical Grade Hemp Oil Market (2026): Market Leaders Powering Global Therapeutics

MARKET INSIGHTS

Global Pharmaceutical Grade Hemp Oil market size was valued at USD 1.87 billion in 2024. The market is projected to grow from USD 2.15 billion in 2025 to USD 4.63 billion by 2032, exhibiting a CAGR of 12.3% during the forecast period.

Pharmaceutical Grade Hemp Oil Market – View in Detailed Research Report

The global Pharmaceutical Grade Hemp Oil market was valued at USD 2.15 billion in 2025 and is projected to reach USD 4.63 billion by 2032, exhibiting a CAGR of 12.3% during the forecast period.

Pharmaceutical Grade Hemp Oil is a highly refined cannabis extract containing high concentrations of cannabidiol (CBD) with negligible THC content (below 0.3%). This premium-grade oil is produced under strict pharmaceutical standards and undergoes rigorous purification processes to remove contaminants while preserving therapeutic compounds. It is increasingly used in medical applications due to its anti‑inflammatory, analgesic, and neuroprotective properties.

🔟 1. Canopy Growth

Headquarters: Vancouver, Canada
Key Offering: Pharmaceutical‑grade CBD oil for prescription and OTC products

Canopy Growth has leveraged its extensive cultivation and extraction infrastructure to become a leading provider of high‑purity CBD oil, focusing on evidence‑based therapeutics for pain, anxiety, and epilepsy.

Sustainability & Growth Initiatives:

• Advanced CO₂ extraction for solvent‑free purity
• GMP‑certified manufacturing facilities
• Carbon‑neutral cultivation and supply chain

9️⃣ 2. ENDOCA

Headquarters: Amsterdam, Netherlands
Key Offering: Full‑spectrum CBD oil for pharmaceutical and nutraceutical applications

ENDOCA specializes in organic hemp cultivation and state‑of‑the‑art extraction, delivering full‑spectrum CBD products that meet stringent European GMP standards.

Sustainability & Growth Initiatives:

• Organic cultivation and biodiversity conservation
• Closed‑loop extraction systems
• Partnerships with academic research institutions

8️⃣ 3. Medical Marijuana

Headquarters: Berlin, Germany
Key Offering: High‑purity CBD isolates for prescription drugs

Medical Marijuana has established a robust R&D pipeline, conducting clinical trials to validate CBD’s efficacy in epilepsy and chronic pain, and securing regulatory approvals across the EU.

Sustainability & Growth Initiatives:

• Compliance with EMA quality and safety guidelines
• Renewable energy‑powered production facilities
• Transparent sourcing and traceability systems

7️⃣ 4. Folium Biosciences

Headquarters: New York, USA
Key Offering: Cannabinoid‑enriched formulations for neurodegenerative disorders

Folium Biosciences focuses on developing cannabinoid therapeutics for Alzheimer’s and Parkinson’s disease, integrating precision medicine approaches with high‑purity CBD extracts.

Sustainability & Growth Initiatives:

• Investment in clinical research and biomarker discovery
• GMP‑certified extraction and formulation labs
• Collaborations with leading universities

6️⃣ 5. Isodiol

Headquarters: San Francisco, USA
Key Offering: CBD‑based therapeutics for chronic pain and anxiety

Isodiol has accelerated product development through partnerships with major pharma companies, aiming to bring CBD‑based prescription drugs to market by 2028.

Sustainability & Growth Initiatives:

• Carbon‑neutral production processes
• Investment in renewable energy for facilities
• Transparent supply chain management

5️⃣ 6. PharmaHemp

Headquarters: Ljubljana, Slovenia
Key Offering: Isolated CBD for dermatological and systemic therapies

PharmaHemp specializes in high‑purity CBD isolates, leveraging advanced purification technologies to deliver pharmaceutical‑grade oils for skin health and systemic conditions.

Sustainability & Growth Initiatives:

• GMP‑certified extraction and packaging
• Renewable energy integration
• Partnerships with European clinical research centers

4️⃣ 7. Elixinol

Headquarters: Sydney, Australia
Key Offering: Premium, naturally derived CBD oils for wellness and medical use

Elixinol focuses on premium, naturally derived products, emphasizing sustainability and high‑quality standards across its product line.

Sustainability & Growth Initiatives:

• Zero‑waste extraction processes
• Organic cultivation and certification
• Community engagement and education programs

3️⃣ 8. NuLeaf Naturals

Headquarters: Irvine, USA
Key Offering: High‑purity CBD oils for medical and wellness applications

NuLeaf Naturals offers a range of pharmaceutical‑grade CBD oils, focusing on clinical validation and consumer safety.

Sustainability & Growth Initiatives:

• GMP‑certified manufacturing
• Carbon‑neutral production facilities
• Transparent ingredient sourcing

2️⃣ 9. HemPoland

Headquarters: Warsaw, Poland
Key Offering: Pharmaceutical‑grade CBD extracts for European markets

HemPoland has built a strong presence in Central Europe, delivering high‑purity CBD products that meet EU regulatory standards.

Sustainability & Growth Initiatives:

• Compliance with EU GMP and safety regulations
• Renewable energy usage in production
• Supply chain transparency initiatives

1️⃣ 10. BAFA GmbH

Headquarters: Munich, Germany
Key Offering: High‑purity CBD oils for therapeutic and cosmetic applications

BAFA GmbH focuses on delivering high‑quality CBD oils for both therapeutic and cosmetic products, leveraging its strong distribution network across Germany and neighboring countries.

Sustainability & Growth Initiatives:

• Carbon‑neutral production and logistics
• Partnerships with German research institutions
• GMP‑certified manufacturing plants

Pharmaceutical Grade Hemp Oil Market – View in Detailed Research Report

Pharmaceutical Grade Hemp Oil Market – View in Detailed Research Report

🌍 Outlook: The Future of Pharmaceutical Grade Hemp Oil Market

The Pharmaceutical Grade Hemp Oil market is poised for accelerated growth, driven by expanding medical applications, regulatory approvals, and consumer demand for natural therapeutics. With a projected CAGR of 12.3% from 2025 to 2032, the market is expected to reach USD 4.63 billion, reflecting increased investment in research, development, and clinical validation across North America, Europe, and emerging markets.

📈 Key Trends Shaping the Market:

• Expansion into neurological and dermatological therapeutics
• Adoption of precision medicine approaches with cannabinoid formulations
• Growth of B2B distribution channels and pharmaceutical partnerships
• Increased focus on sustainability and carbon‑neutral production
• Regulatory harmonization across global markets facilitating market entry